Table 1 Clinical and laboratory characteristics of 304 patients associated with overall survival (OS)
Patient characteristics | No. of patients (%) | Median OS (IQR) | P-valuea |
|---|---|---|---|
Gender | |||
Male | 232 (76.3%) | 44.2 (38.5–47.4) | 0.967 |
Female | 72 (23.7%) | 44.8 (40.7–46.8) | |
Age (years) | |||
≤46 | 157 (51.6%) | 45.0 (40.6–47.8) | 0.202 |
> 46 | 147 (48.4%) | 43.4 (37.2–46.8) | |
Tumor stage | |||
T1–2 | 52 (17.1%) | 46.2 (41.9–49.8) | 0.043 |
T3–4 | 252 (82.9%) | 44.0 (38.3–46.9) | |
Node stage | |||
N0–1 | 168 (55.3%) | 44.5 (40.8–47.0) | 0.007 |
N2–3 | 136 (44.7%) | 43.9 (36.0–47.8) | |
TNM stageb | |||
I–II | 33 (10.9%) | 45.8 (41.3–48.0) | 0.048 |
III–IV | 271 (89.1%) | 44.2 (39.2–47.1) | |
Treatment | |||
Radiotherapy | 43 (14.1%) | 44.0 (40.7–48.1) | 0.047 |
Chemoradiotherapy | 261 (85.9%) | 44.4 (38.7–47.0) | |
CRP (mg/L) | |||
≤ 2.03 | 131 (43.1%) | 44.6 (41.9–47.4) | 0.001 |
> 2.03 | 173 (56.9%) | 44.1 (36.0–47.0) | |
SAA (mg/L) | |||
≤ 4.46 | 154 (50.7%) | 44.7 (41.7–47.4) | 0.001 |
> 4.46 | 150 (49.3%) | 43.3 (35.2–47.1) | |
PLR | |||
≤ 141.52 | 167 (54.9%) | 44.0 (40.1–47.0) | 0.287 |
> 141.52 | 137 (45.1%) | 45.1 (37.2–47.5) | |
NLR | |||
≤ 2.62 | 149 (49.0%) | 44.2 (40.6–47.5) | 0.006 |
> 2.62 | 155 (51.0%) | 44.5 (36.1–47.0) | |
LMR | |||
≤ 1.87 | 29 (9.5%) | 45.3 (42.1–50.3) | 0.415 |
> 1.87 | 275 (90.5%) | 44.2 (39.2–47.0) | |
EBV DNA (copies/mL) | |||
≤ 2340 | 161 (53.0%) | 45.0 (40.9–47.6) | <0.001 |
> 2340 | 143 (47.0%) | 43.4 (36.0–46.4) | |